cannabis drug ipo
Cannabis IPOs vs Biotech: Does Reclassification Count?
Reclassification of industrial hemp has improved IPO prospects, yet investor returns still depend on drug development milestones, as 36% of developers filed new INDs after the 2026 schedule change. The move lowered legal barriers but left state-federal gaps. I have watched several companies navigate this new terrain. Medical Disclaimer: This